What the research found

Menopausal weight gain stems primarily from estrogen loss, not metabolic dysfunction in the conventional sense. Yet the standard approach—prescribing a GLP-1 or dual agonist alone—addresses only appetite and fat loss while leaving the hormonal deficit untouched. The concern is tissue-selective: GLP-1 medications cause between 25–40% of weight loss to come from lean mass (muscle and bone) depending on the agent, while menopause independently drives bone mineral density loss of roughly 2% annually during the transition window, with spine loss exceeding hip loss.

A recent Mayo Clinic retrospective followed 120 postmenopausal women on tirzepatide for at least 12 months, comparing outcomes in those receiving concurrent menopause hormone therapy versus those on the GLP-1 alone. The source text cuts off before presenting those results, but the framing suggests women combining both interventions showed superior body composition outcomes—specifically, fat loss without proportional lean mass decline.

Why it matters for you

If you're tracking body composition via DEXA or similar imaging while on a GLP-1, the number on the scale can mask what's actually happening in your tissues. A 10-pound loss might represent 6 pounds of fat and 4 pounds of muscle—a trade you didn't knowingly make. For menopausal and perimenopausal users, this becomes compounded: you're losing muscle during a life stage where estrogen withdrawal is already nudging bone and lean mass downward.

The practical implication: resist treating GLP-1 as a standalone solution. If you're menopausal or perimenopausal and considering these medications, the evidence suggests requesting baseline body composition and bone density scans before starting, then reassessing at regular intervals. Protein intake becomes non-negotiable—your target shouldn't be generic but calculated from your baseline scan. Resistance training shifts from "nice to have" to structural protection; it literally signals your body to preserve muscle during weight loss.

For those already on a GLP-1, the hormone therapy question deserves a conversation with a clinician familiar with both. Estrogen and GLP-1s operate on different systems: hormones restore signaling and defend skeletal health; GLP-1s suppress appetite and reduce visceral fat. They're complementary, not competing.

Caveats

• The Mayo study data are presented incompletely in the source; effect sizes and statistical significance are not stated
• Observational clinic data ("the pattern I see") are explicitly not trial data and describe a self-selected patient population already receiving comprehensive monitoring (baseline scans, protein counseling, resistance training prescription)
• No head-to-head trial evidence is cited for combined GLP-1 + hormone therapy versus GLP-1 alone in menopausal women
• Hormone therapy candidacy varies widely; contraindications (personal/family breast cancer history, clotting risk) are not addressed in this briefing
• The SWAN cohort data on lean mass loss (0.2% annually) are described as "modest" and may not apply uniformly across individuals